Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a morbid malignancy with
discouraging survival rates. Enthusiasm for pre-operative therapy (chemotherapy, radiation …

Background Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment
for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal …

Objective: This nationwide multicenter study aimed to define clinically relevant thresholds of
relative serum CA19-9 response after 2 months of induction chemotherapy in patients with …

Objective: To characterize associations between carbohydrate antigen 19–9 (CA19–9)
dynamics during neoadjuvant therapy (NT) and survival for patients with pancreatic ductal …

Background Overall survival (OS) for operable pancreatic cancer (PC) is optimized when 4–
6 months of nonsurgical therapy is combined with pancreatectomy. Because surgery …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …

Background Several international high-volume centers have reported good outcomes after
resection of locally advanced pancreatic cancer (LAPC) following chemo (radio) therapy, but …

BACKGROUND: FOLFIRINOX is increasingly used in the management of pancreatic ductal
adenocarcinoma (PDAC). However, neoadjuvant therapy is associated with toxicity …

One of the most severe and devastating cancer is pancreatic cancer. Pancreatic ductal
adenocarcinoma (PDAC) is one of the major pancreatic exocrine cancer with a poor …